Polymer-based platform could make administration of biologics more convenient, more efficacious, and safer.

MediVas and Pfizer will collaborate on R&D related to delivery methods for Pfizer compounds to treat eye diseases. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, the companies hope to create a product that can change the paradigm of how ophthalmic treatments are administered.

“We are confident that by combining Pfizer’s compounds with our polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye,” remarks Kenneth W. Carpenter, MediVas’ president and CEO.

Previous articleKirin and Astellas Partner to Develop Immunosuppressive Mab
Next articleBioServe, Harvard, and University of Michigan to Determine Link Between Genetics and Lead Exposure